135 filings
8-K
PTCT
PTC Therapeutics Inc
29 Feb 24
Results of Operations and Financial Condition
4:15pm
8-K
PTCT
PTC Therapeutics Inc
25 Jan 24
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
4:06pm
8-K
PTCT
PTC Therapeutics Inc
8 Jan 24
Results of Operations and Financial Condition
9:27am
8-K
PTCT
PTC Therapeutics Inc
26 Oct 23
Results of Operations and Financial Condition
4:07pm
8-K
PTCT
PTC Therapeutics Inc
19 Oct 23
Termination of a Material Definitive Agreement
4:15pm
8-K
j0eykt r4ontf8jq
19 Oct 23
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
8:03am
8-K
hrft5c76946a h0
28 Sep 23
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
4:45pm
8-K
dkrihqnax61oatc65
22 Sep 23
Other Events
9:00am
8-K
zvnf16u75579l 3wh1j
15 Sep 23
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
6:15am
8-K
w9xmtu7tz8efiityx 7t
3 Aug 23
Results of Operations and Financial Condition
4:03pm
8-K
tu8ca352
19 Jul 23
Regulation FD Disclosure
12:00pm
8-K
gcbf7e5
17 Jul 23
Departure of Directors or Certain Officers
4:46pm
8-K
38hw6h9
21 Jun 23
Regulation FD Disclosure
7:30am
8-K
q7i1p7ixmy7pdm7 2dut
6 Jun 23
Submission of Matters to a Vote of Security Holders
4:04pm
8-K
ibw44yh913pm2q4
23 May 23
PTC Therapeutics Announces Strategic Pipeline Prioritization
5:17pm
8-K
3s02n2btgzzyc4n
17 May 23
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
7:04am
8-K
7jywe9bxvtbfwv9
27 Apr 23
Results of Operations and Financial Condition
4:02pm
8-K
6351 u854lme
18 Apr 23
Departure of Directors or Certain Officers
5:11pm
8-K
uhxwm 7eshih9mg5y8
24 Mar 23
Departure of Directors or Certain Officers
7:45am
8-K
wes4 t3m91f62
21 Feb 23
Results of Operations and Financial Condition
4:07pm